K. Rolfe

Drisapersen treatment for Duchenne muscular dystrophy (DMD): results of a randomized, double-blind, placebo-controlled clinical trial of two doses for 24 weeks, followed by a 24-week post-treatment period

J. Kraus, C. McDonald, G. Campion, 2014 .

Randomized placebo controlled trial to assess the role of intracervical lignocaine in outpatient hysteroscopy

A. Magos, N. Hill, K. Rolfe, 1992, British journal of obstetrics and gynaecology.

Safety and efficacy of drisapersen for the treatment of Duchenne muscular dystrophy (DEMAND II): an exploratory, randomised, placebo-controlled phase 2 study

V. Ricotti, F. Muntoni, L. Servais, 2014, The Lancet Neurology.

Tafenoquine co-administered with dihydroartemisinin–piperaquine for the radical cure of Plasmodium vivax malaria (INSPECTOR): a randomised, placebo-controlled, efficacy and safety study

I. Elyazar, R. Noviyanti, D. Subekti, 2023, The Lancet. Infectious diseases.

A pharmacometrics approach to assess the feasibility of capillary microsampling to replace venous sampling in clinical studies: Tafenoquine case study

N. Goyal, S. Duparc, Sagar S. Bachhav, 2022, British journal of clinical pharmacology.

Tafenoquine for the radical cure versus prophylaxis of Plasmodium vivax malaria: the importance of using the appropriate data set

Raman Sharma, Chao Chen, K. Rolfe, 2023, The Indian journal of medical research.